Preferential rights issue 2021 - Alligator Bioscience

Alligator Bioscience announced on December 15, 2020 its decision to perform a preferential rights issue.

Preliminary timeline

December 30, 2020 - Last day of trading incl. preferential rights
December 30, 2020 - Publication of prospectus
January 4, 2021 – First day of trading excl. preferential rights
January 5, 2021 – Record date
January 11 – January 21, 2021 – Trading in rights
January 11 – January 25, 2021 – Subscription period
January 11, 2021 – Until the Rights Issue is registered at the Swedish Companies Registration Office – Trading in paid subscription share (Sw. “BTA”)
January 28, 2021 – Estimated publication of outcome of Rights Issue

IMPORTANT INFORMATION

Due to legal restrictions, the information on this part of Alligator Bioscience AB’s (”Alligator”) website is not accessible to certain persons. We kindly ask you to review the following information and provide the following confirmation each time you wish to access these websites. Please note that the terms set out below may be altered or updated and therefore it is important that you review them each time you visit this page.

The information contained in this section of Alligator’s website is not intended for, and must not be accessed by, distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States, Canada, New Zealand, South Africa, Japan, Australia, South Korea, Hong Kong, Switzerland, Singapore or any other jurisdiction where distribution would require additional prospectuses, registration measures or other measures besides those required by Swedish or otherwise would be in conflict with the rules of such jurisdiction or which cannot be made without application of exemptions in such jurisdictions. The information on the websites does not constitute any offer regarding subscription rights, paid subscribed shares or shares in Alligator (“Securities”) to any person in said jurisdictions. The information on the websites may not be forwarded or reproduced in such a manner that contravenes such restrictions or gives cause to such requirements.

No Securities have been or will be registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction in the United States and may not be offered, subscribed for, used, pledged, sold, resold, allotted, delivered or otherwise transferred, directly or indirectly, in or into the United States except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States.

Within the European Economic Area (“EEA”), no public offering of Securities is made in other countries than Sweden. In other member states of the European Union (“EU”), such an offering of Securities may only be made in accordance with the Prospectus Regulation (EU) 2017/1129 (the “Prospectus Regulation”). In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In order to be eligible to view the information on the following web page, you shall be deemed, by accessing the following web page, to have confirmed and represented that (i) you have read and accepted the terms and restrictions set out above, and (ii) you are not located in the United States, Canada, New Zealand, South Africa, Japan, Australia, South Korea, Hong Kong, Switzerland, Singapore or in any other jurisdiction where the release, distribution or publication of the information would be unlawful according to applicable law or regulations.

Alligator Bioscience

The offering in summary

Prospectus

Financial reports & other documentation

Pressreleases

IMPORTANT INFORMATION